TY - JOUR AU1 - Cohen, Elisabeth J. AB - EDITORIAL We Need to Do Better ERPES ZOSTER (HZ) IS A COMMON, SERI- than 70s or 80s; however, reduction in disease burden ous, and preventable disease. Despite the was 66% in all age groups. In a more recent and larger approval of a safe and effective vaccine population-based study, including more patients with in 2006 for immunocompetent pa- chronic diseases, efficacy of 55% was observed in all age H tients aged 60 years or older, underuse groups. In a recent randomized clinical trial, almost 70% 1,2 of this vaccine remains widespread. Understanding the efficacy in disease prevention was observed in patients in barriers to recommended use and implementation of pro- their 50s. Currently, the vaccine is recommended by the grams to overcome them is critically important in de- Centers for Disease Control and Prevention (CDC) for im- creasing this often devastating disease. Somewhat sur- munocompetent patients aged 60 years and older, includ- prisingly, the most important barrier is lack of a strong ing people with a history of HZ and no known history of physician recommendation for this vaccine. We must do chicken pox; it is also Food and Drug Administration– better so that physicians know about zoster and TI - Prevention of Herpes Zoster JF - JAMA Ophthalmology DO - 10.1001/jamaophthalmol.2013.588 DA - 2013-03-01 UR - https://www.deepdyve.com/lp/american-medical-association/prevention-of-herpes-zoster-55JtCqMFHH SP - 396 EP - 398 VL - 131 IS - 3 DP - DeepDyve ER -